 | Up a level |
Wirsching, H-G; Tabatabai, G; Roelcke, U; Hottinger, A F; Jörger, F; Schmid, A; Plasswilm, Ludwig; Schrimpf, D; Mancao, C; Capper, D; Conen, K; Hundsberger, T; Caparrotti, F; von Moos, R; Riklin, C; Felsberg, J; Roth, P; Jones, D T W; Pfister, S; Rushing, E J; ... (2018). Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Annals of oncology, 29(6), pp. 1423-1430. Oxford University Press 10.1093/annonc/mdy120
Stummer, W; Meinel, T; Ewelt, C; Martus, P; Jakobs, O; Felsberg, J; Reifenberger, G; Gilsbach, J; Oertel, M; Franz, K; Oszvald, A; Stretz, T; Böker, DK; Neslter, U; Oppel, F; Brune, A; Rohde, V (2012). Prospective cohort study of radiotherapy with concomitant and adjuvant temolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. Journal of neuro-oncology, 108(1), pp. 89-97. Boston, Mass.: Springer 10.1007/s11060-012-0798-3
